Cutaneous toxic effects of targeted therapy: clinical manifestations and correction

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Targeted therapy used in oncology today is the most effective, but frequent cutaneous side effects force to reduce dose or interrupt treatment, significantly reducing the anti-tumor effect. The data on the pathogenesis of toxic skin reactions and the most frequent clinical manifestations (papular-pustular reaction, hand-foot syndrome) according to various studies are presented. The basic principles of correction are described. Examples of anticancer drug doses correlation and severity of skin reactions are presented.

Full Text

Restricted Access

About the authors

Eugenia A. Shatokhina

Federal State Institution of Additional Rostgraduate Education Central State Medical Academy Department for Rresidential Affairs of the Russian Federation; Moscow Scientific and Rractical Center of dermatology and cosmetology Moscow Health Department

Email: e.a.shatokhina@gmail.com
Moscow, 121359, Russian Federation
MD, PhD, Central State Medical Academy

K. V Kotenko

Federal State Institution of Additional Rostgraduate Education Central State Medical Academy Department for Rresidential Affairs of the Russian Federation

Moscow, 121359, Russian Federation

L. S Kruglova

Moscow Scientific and Rractical Center of dermatology and cosmetology Moscow Health Department

Moscow, 107564, Russian Federation

References

  1. Harandi A., Zaidi A.S., Stocker A.M., Laber D.A. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J. Oncol. 2009; 2009: 567486. doi: 10.1155/2009/567486.
  2. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009; 6(8): 465-77.
  3. Чубенко В.А. Осложнения таргетной терапии. Практическая онкология. 2010; 11(3): 192-202.
  4. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995; 19(3): 183-232.
  5. Nanney L.B., McKanna J.A., Stoscheck C.M., Carpenter G., King L.E. Visualization of epidermal growth factor receptors in human epidermis. J. Invest. Dermatol. 1984; 82(2): 165-9.
  6. Green M.R., Couchman J.R. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J. Invest. Dermatol. 1985; 85(3): 239-45.
  7. Pierard-Franchimont C., Colige A., Arrese Estrada J., Lapiere C.M., Pierard G.E. Immunohistochemical expression of epidermal growth factor receptors in nuclei of a subpopulation of keratinocytes and sweat gland cells. Dermatologica. 1991; 183(1): 7-9.
  8. Nanney L.B., Stoscheck C.M., King L.E.Jr., Underwood R.A., Holbrook K.A. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J. Invest. Dermatol. 1990; 94(6): 742-8.
  9. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Rev. Сancer. 2006; 6(10): 803-12.
  10. Lacouture M.E., Lai S.E. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, Dryness due to EGFR inhibitors) syndrome. Br. J. Dermatol. 2006; 155(4): 852-4.
  11. Chu D., Lacouture M.E., Fillos T., Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008; 47(2): 176-86. doi: 10.1080/02841860701765675.
  12. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 2005; 31(6): 456-73.
  13. Azad S., Aragon-Ching J.B., Dahut W.L., Gutierrez M., Figg W.D., Jain L., et al. Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy Nilofer. Clin. Cancer. Res. 2009; 15(4): 1411-6.
  14. Segaert S., Chiritescu G., Lemmens L., Dumon K., van Cutsem E., Tejpar S. Skin toxicities of targeted therapies. Eur. J. Cancer. 2009; 45(Suppl. 1): 295-308. doi: 10.1016/S0959-8049(09)70044-9.
  15. Porta C., Paglino C., Imarisio I., Bonomi L. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin. Exp. Med. 2007; 72(4): 127-34.
  16. Strumberg D., Awada A., Hirte H., Clark J.W., Seeber S., Piccart P., et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur. J. Cancer. 2006; 42(4): 548-56.
  17. Tsai K.Y., Yang C.H., Kuo T.T., Hong H.S., Chang J.W. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J. Clin. Oncol. 2006; 24(36): 5786-8.
  18. Morita E., Lee D.G., Sugiyama M., Yamamoto S. Expression of c-kit ligand in human keratinocytes. Arch. Dermatol. Res. 1994; 286(5): 273-7.
  19. Jacot W., Bessis D., Jorda E., Ychou M., Fabbro M., Pujol J.L., Guillot B. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Br. J. Dermatol. 2004; 151(1): 238-41.
  20. Saltz L.B., Meropol N.J., Loehrer P.J.Sr., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004; 22(7): 1201-8.
  21. Xiong H.Q., Rosenberg A., LoBuglio A., Schmidt W., Wolff R.A., Deutsch J., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J. Clin. Oncol. 2004; 22(13): 2610-6.
  22. Perez-Soler R., Delord J.P., Halpern A., Kelly K., Krueger J., Sureda B.M., et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005; 10(5): 345-56.
  23. Galimont-Collen A.F., Vos L.E., Lavrijsen A.P., Ouwerkerk J., Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur. J. Cancer. 2007; 43(5): 845-51.
  24. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Accessed March 20, 2008. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
  25. Gomez P., Lacouture M.E. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist. 2011; 16(11): 1508-19.
  26. De Wit M., Boers-Doets C.B., Saettini A., Vermeersch K., de Juan C.R., Ouwerkerk J., et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer. 2014; 22(3): 837-46.
  27. McLellan B., Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol. Ther. 2011; 24(2): 396-400. doi: 10.1111/j.1529-8019.2011.01435.x.
  28. Lacouture M.E., Wu S., Robert C., Atkins M.B., Kong H.H., Guitart J., et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008; 13(9): 1001-11.
  29. Autier J., Escudier B., Wechsler J., Spatz A., Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch. Dermatol. 2008; 144(7): 886-92.
  30. Anderson R., Jatoi A., Robert C., Wood L.S., Keating K.N., Lacouture M.E. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009; 14(3): 291-302. doi: 10.1634/theoncologist.2008-0237.
  31. Круглова Л.С., Жукова О.В., Коррекция побочных эффектов противоопухолевой терапии сорафенибом. Клиническая дерматология и венерология. 2015; 3: 94-8.
  32. Инструкция по применению лекарственного препарата для медицинского применения Нексавар № ЛСР-000093 от 19.03.2014. http://pharma.bayer.ru/scripts/pages/ru/catalog/nexavar.php
  33. Shepherd F.A., Rodriques Pereira J., Ciuleanu T. Tan E.H., Hirsh V., Thongprasert S. et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previoulsy treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353(2): 123-32.
  34. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006; 354(6): 567-78.

Statistics

Views

Abstract - 31

PDF (Russian) - 1

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2016 Shatokhina E.A., Kotenko K.V., Kruglova L.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies